{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 89 of 92', 'CR845-CLIN3102', '14.6', 'Appendix 6: Short Opiate Withdrawal Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'INSTRUCTIONS: Please mark the appropriate box if you have suffered from any of the', 'following conditions in the LAST 24 HOURS:', '0', '1', '2', '3', 'NONE', 'MILD', 'MODERATE', 'SEVERE', '1. Feeling sick', '2. Stomach cramps', '3. Muscle spasms/twitching', '4. Feelings of coldness', '5. Heart pounding', '6. Muscular tension', '7. Aches and pains', '8. Yawning', '9. Runny eyes', '10. Insomnia/problems sleeping', 'Date Completed:', 'Time:', 'SUBJECT INITIALS', 'First', 'Middle', 'Last', '.', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 91 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 90 of 92', 'CR845-CLIN3102', '14.7', 'Appendix 7: Objective Opiate Withdrawal Scale', 'This is a representation of the content of the instrument to be used. Please refer to the', 'Study Reference Manual for the instrument to be administered to patients and', 'instructions.', 'INSTRUCTIONS: Observe the patient during a 5 MINUTE period, then indicate a score', 'for each of the items listed below:', '0', '1', '1. Yawning', 'no yawns', '1 yawn', '2. Rhinorrhea', '< 3 sniffs', '3 sniffs', '3. Piloerection (observe arm)', 'absent', 'present', '4. Perspiration', 'absent', 'present', '5. Lacrimation', 'absent', 'present', '6. Tremor (hands)', 'absent', 'present', '7. Mydriasis', 'absent', '3 mm', '8. Hot and Cold flushes', 'absent', 'shivering / huddling for warmth', '9. Restlessness', 'absent', 'frequent shifts of position', '10. Vomiting', 'absent', 'present', '11. Muscle twitches', 'absent', 'present', '12. Abdominal cramps', 'absent', 'Holding stomach', '13. Anxiety', 'absent', 'mild severe', 'Date Completed:', 'Time:', '2', '0', 'D', 'D', 'M', 'M', 'M', 'Y', 'Y', 'Y', 'Y', 'AM', 'PM', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 92 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 91 of 92', 'CR845-CLIN3102', '15.0', 'Statistical Appendix', 'This appendix provides further details related to the treatment of missing data for the', 'primary and sensitivity analyses of the primary endpoint.', 'For multiple imputations and other instances where random seeds are required, the values', 'used (in order) are:', '8392857', '2985729', '1843255', '9086284', '5547484', '8017456', '9597295', '2252256', '4821871', '9852467', '5126715', '3232132', '9841654', '3645284', '1587345', 'Note that not all seeds may be required in programming the multiple imputations. If', 'additional seeds are needed, they will be chosen by adding 1 to each of the values above,', 'again using them in order.', 'The number of imputations for the multiple imputations will be 20.', 'For the primary analysis, a multi-stage process will be applied:', 'Stage 1: Subjects will have their 11-point NRS scores imputed. First, using all visits,', 'intermittent missing data will be imputed using the Markov Chain Monte Carlo (MCMC)', 'method implemented with the SAS MI procedure; data imputed following subject', 'discontinuation via this process will be censored out of the resulting dataset so that only', 'intermittent missing data is imputed via this method. Second, monotone missing data', 'will be imputed following subject discontinuation using SAS proc MI. For each stage,', 'MI will be performed within treatment group with covariates for baseline NRS score, use', 'of prior anti-itch medication, and presence of select medical conditions. Should', 'convergence issues occur due to small cell size for the one or both of the categorical', 'covariates at either stage, the appropriate covariate(s) will be removed from the model.', 'Stage 2: Using the resulting complete datasets, the change from baseline with respect to', 'the 11-point NRS will be calculated; patients will be categorized as responder if they', 'have a 3-point (or greater) improvement over baseline. Week 12 values will serve as the', 'primary timepoint. The 20 MI runs will be analyzed independently using a logistic', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 93 of 95']\n\n###\n\n", "completion": "END"}